This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Prostate Cancer
  • /
  • Exploitation of CD133 for the targeted imaging of ...

Exploitation of CD133 for the targeted imaging of lethal prostate cancer.

Read time: 1 mins
Published:15th Nov 2019
Author: Glumac PM, Gallant JP, Shapovalova M, Li Y, Murugan P, Gupta S et al.
Availability: Pay for access, or by subscription
Ref.:Clin Cancer Res. 2019. pii: clincanres.1659.2019.

Purpose: Aggressive variant prostate cancer (AVPC) is a non-androgen receptor-driven form of disease that arises in men who have failed standard-of-care therapies. Therapeutic options for AVPC are limited, and the development of novel therapeutics is significantly hindered by the inability to accurately quantify patient response to therapy by imaging. Imaging modalities that accurately and sensitively detect the bone and visceral metastases associated with AVPC do not exist.

Experimental design: This study investigated the transmembrane protein CD133 as a targetable cell surface antigen in AVPC. We evaluated the expression of CD133 by microarray and immunohistochemistry analysis. The imaging potential of the CD133-targeted IgG (HA10 IgG) was evaluated in preclinical prostate cancer models using two different imaging modalities: near-infrared and positron emission tomography (PET) imaging.

Results: Evaluation of the patient data demonstrated that CD133 is overexpressed in a specific phenotype of AVPC that is androgen receptor-indifferent and neuroendocrine differentiated. Additionally, HA10 IgG was selective for CD133-expressing tumors in all preclinical imaging studies. PET imaging with [89Zr]Zr-HA10 IgG revealed a mean %ID/g of 24.30±3.19 in CD133-positive metastatic lesions as compared to 11.82±0.57 in CD133-negative lesions after 72 hours (p=0.0069). Ex vivo biodistribution showed similar trends as signals were increased by nearly 3-fold in CD133-positive tumors (p<0.0001).

Conclusions: To our knowledge, this is the first study to define CD133 as a targetable marker of AVPC. Similarly, we have developed a novel imaging agent which is selective for CD133-expressing tumors, resulting in a non-invasive PET imaging approach to more effectively detect and monitor AVPC.

Read abstract on library site

Access full article